Transcriptional reprogramming by mutated IRF4 in lymphoma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 11 2023
Historique:
received: 29 11 2022
accepted: 20 09 2023
medline: 9 11 2023
pubmed: 8 11 2023
entrez: 7 11 2023
Statut: epublish

Résumé

Disease-causing mutations in genes encoding transcription factors (TFs) can affect TF interactions with their cognate DNA-binding motifs. Whether and how TF mutations impact upon the binding to TF composite elements (CE) and the interaction with other TFs is unclear. Here, we report a distinct mechanism of TF alteration in human lymphomas with perturbed B cell identity, in particular classic Hodgkin lymphoma. It is caused by a recurrent somatic missense mutation c.295 T > C (p.Cys99Arg; p.C99R) targeting the center of the DNA-binding domain of Interferon Regulatory Factor 4 (IRF4), a key TF in immune cells. IRF4-C99R fundamentally alters IRF4 DNA-binding, with loss-of-binding to canonical IRF motifs and neomorphic gain-of-binding to canonical and non-canonical IRF CEs. IRF4-C99R thoroughly modifies IRF4 function by blocking IRF4-dependent plasma cell induction, and up-regulates disease-specific genes in a non-canonical Activator Protein-1 (AP-1)-IRF-CE (AICE)-dependent manner. Our data explain how a single mutation causes a complex switch of TF specificity and gene regulation and open the perspective to specifically block the neomorphic DNA-binding activities of a mutant TF.

Identifiants

pubmed: 37935654
doi: 10.1038/s41467-023-41954-8
pii: 10.1038/s41467-023-41954-8
pmc: PMC10630337
doi:

Substances chimiques

DNA 9007-49-2
Interferon Regulatory Factors 0
interferon regulatory factor-4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6947

Informations de copyright

© 2023. The Author(s).

Références

Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Blood. 2019 Sep 5;134(10):802-813
pubmed: 31292115
Nat Commun. 2018 Aug 6;9(1):3090
pubmed: 30082823
Nucleic Acids Res. 2005 Sep 07;33(16):e137
pubmed: 16147984
Haematologica. 2012 Oct;97(10):1612-4
pubmed: 22581005
Immunity. 2017 Sep 19;47(3):481-497.e7
pubmed: 28930660
Cell. 2012 Oct 12;151(2):289-303
pubmed: 23021777
Nucleic Acids Res. 2021 Jun 21;49(11):6249-6266
pubmed: 34060631
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Nucleic Acids Res. 2016 May 5;44(8):3567-85
pubmed: 26673693
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Med. 2010 May;16(5):571-9, 1p following 579
pubmed: 20436485
Methods Mol Biol. 2019;1956:61-75
pubmed: 30779030
Mol Cell. 2002 Nov;10(5):1097-105
pubmed: 12453417
Nature. 2012 Oct 25;490(7421):502-7
pubmed: 22992524
Bioinformatics. 2009 Jun 1;25(11):1422-3
pubmed: 19304878
Cancer Cell. 2012 Jun 12;21(6):723-37
pubmed: 22698399
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Leukemia. 2023 Nov;37(11):2237-2249
pubmed: 37648814
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420-5
pubmed: 23840064
Nucleic Acids Res. 2001 Jul 1;29(13):2860-74
pubmed: 11433033
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 2009 Nov 12;462(7270):182-8
pubmed: 19907488
Oncogene. 2011 Apr 14;30(15):1831-40
pubmed: 21119597
Nature. 2001 Jul 19;412(6844):341-6
pubmed: 11460166
Bioinformatics. 2021 Jul 12;37(11):1607-1609
pubmed: 33135764
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Leukemia. 2018 Sep;32(9):1994-2007
pubmed: 29588546
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4513-22
pubmed: 25288773
Curr Opin Struct Biol. 2017 Dec;47:1-8
pubmed: 28349863
Blood. 2012 Nov 29;120(23):4609-20
pubmed: 22955914
Bioinformatics. 2011 Dec 15;27(24):3423-4
pubmed: 21949271
EMBO J. 1999 Feb 15;18(4):977-91
pubmed: 10022840
Sci Rep. 2021 May 4;11(1):9465
pubmed: 33947895
Gigascience. 2018 Dec 1;7(12):
pubmed: 30277498
Haematologica. 2011 Jun;96(6):863-70
pubmed: 21393330
Blood. 2000 Mar 15;95(6):2084-92
pubmed: 10706878
Nature. 2009 Oct 29;461(7268):1248-53
pubmed: 19865164
Bioinformatics. 2004 Nov 22;20(17):3246-8
pubmed: 15180930
Mol Cell. 2013 Oct 10;52(1):25-36
pubmed: 24076218
Blood. 2002 Apr 15;99(8):3060-2
pubmed: 11929801
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
EMBO J. 2016 Mar 1;35(5):515-35
pubmed: 26796577
Gene Ther. 2000 Jun;7(12):1063-6
pubmed: 10871756
J Clin Invest. 2003 Feb;111(4):529-37
pubmed: 12588891
Nat Immunol. 2006 Feb;7(2):207-15
pubmed: 16369535
Immunity. 2017 Aug 15;47(2):268-283.e9
pubmed: 28778586
EMBO J. 2002 Aug 1;21(15):4104-13
pubmed: 12145210
Nat Commun. 2018 Dec 6;9(1):5218
pubmed: 30523256
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
J Mol Biol. 2016 Feb 22;428(4):720-725
pubmed: 26410586
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Nature. 2012 Sep 6;489(7414):75-82
pubmed: 22955617
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nat Commun. 2022 Feb 4;13(1):700
pubmed: 35121733
Blood. 2017 Jan 19;129(3):333-346
pubmed: 27864294
Nat Mach Intell. 2021 Mar;3(3):258-266
pubmed: 34322657
Nat Immunol. 2011 Sep 20;12(10):933-40
pubmed: 21934679
Nature. 2011 Sep 11;478(7367):64-9
pubmed: 21909114
Genes Chromosomes Cancer. 2016 Mar;55(3):251-67
pubmed: 26608593
Science. 2012 Nov 16;338(6109):975-80
pubmed: 22983707
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Blood. 2006 Mar 15;107(6):2493-500
pubmed: 16304050
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Nat Rev Cancer. 2019 Nov;19(11):611-624
pubmed: 31511663
Nature. 1982 Sep 2;299(5878):65-7
pubmed: 7110326
Cell Rep. 2015 Aug 4;12(5):821-36
pubmed: 26212328
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Cell Biol. 1995 Apr;15(4):2071-9
pubmed: 7891702
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):880-889
pubmed: 30598445
Cancer Cell. 2020 Oct 12;38(4):534-550.e9
pubmed: 32888433
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Cell Death Differ. 2018 Jan;25(1):154-160
pubmed: 29099487
Nat Rev Immunol. 2007 Feb;7(2):105-17
pubmed: 17259967
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Blood. 2015 Jan 1;125(1):124-32
pubmed: 25359993
Cancer Discov. 2019 Jun;9(6):796-811
pubmed: 31018969
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
Immunol Rev. 2012 May;247(1):73-92
pubmed: 22500833
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Nature. 2006 May 4;441(7089):106-10
pubmed: 16572121
Immunity. 2013 May 23;38(5):918-29
pubmed: 23684984
Sci Rep. 2019 Jun 27;9(1):9354
pubmed: 31249361
Genome Biol. 2023 Jun 27;24(1):154
pubmed: 37370113
Immunol Rev. 1998 Apr;162:153-60
pubmed: 9602361
BMC Bioinformatics. 2010 May 11;11:237
pubmed: 20459804
Nature. 2012 Oct 25;490(7421):543-6
pubmed: 22992523
Immunity. 2006 Aug;25(2):225-36
pubmed: 16919487
Nucleic Acids Res. 2013 Nov;41(21):e201
pubmed: 24071585
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Nat Immunol. 2006 Jul;7(7):773-82
pubmed: 16767092
Genes Dev. 1988 Apr;2(4):383-93
pubmed: 3371658
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Cancer Cell. 2021 Mar 8;39(3):380-393.e8
pubmed: 33689703
Nat Rev Immunol. 2013 Jul;13(7):499-509
pubmed: 23787991
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nucleic Acids Res. 1995 Jun 25;23(12):2127-36
pubmed: 7541907
Leukemia. 2018 Jan;32(1):92-101
pubmed: 28659618
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Nucleic Acids Res. 2019 Jul 2;47(W1):W35-W42
pubmed: 31114906
Mol Cell Biol. 1993 Aug;13(8):4531-8
pubmed: 7687740
Nat Genet. 2022 Sep;54(9):1376-1389
pubmed: 36050548
Nature. 1998 Mar 5;392(6671):42-8
pubmed: 9510247
Bioinformatics. 2008 Jul 1;24(13):1547-8
pubmed: 18467348
Nat Immunol. 2017 May;18(5):563-572
pubmed: 28346410
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Nature. 1998 Jan 1;391(6662):103-6
pubmed: 9422515
Genes Dev. 1995 Jun 1;9(11):1377-87
pubmed: 7797077
Nat Rev Cancer. 2009 Jan;9(1):15-27
pubmed: 19078975
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
Nat Commun. 2018 Apr 10;9(1):1366
pubmed: 29636450
Eur J Immunol. 2014 Jul;44(7):1886-95
pubmed: 24782159
Sci Immunol. 2023 Jan 20;8(79):eade7953
pubmed: 36662884

Auteurs

Nikolai Schleussner (N)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.
Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.
Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany.

Pierre Cauchy (P)

Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
University Medical Center Freiburg, 79106, Freiburg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Vedran Franke (V)

Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany.

Maciej Giefing (M)

Institute of Human Genetics, Polish Academy of Sciences, Poznan, 60-479, Poland.
Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany.

Oriol Fornes (O)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada.

Naveen Vankadari (N)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3000, Australia.

Salam A Assi (SA)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

Mariantonia Costanza (M)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.
Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.
Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany.

Marc A Weniger (MA)

Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany.

Altuna Akalin (A)

Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany.

Ioannis Anagnostopoulos (I)

Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany.

Thomas Bukur (T)

TRON gGmbH - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany.

Marco G Casarotto (MG)

Research School of Biology, The Australian National University, Canberra, ACT, Australia.

Frederik Damm (F)

Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.

Oliver Daumke (O)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany.

Benjamin Edginton-White (B)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

J Christof M Gebhardt (JCM)

Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany.

Michael Grau (M)

Department of Physics, University of Marburg, 35052, Marburg, Germany.
Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.

Stephan Grunwald (S)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany.

Martin-Leo Hansmann (ML)

Frankfurt Institute of Advanced Studies, Frankfurt am Main, Germany.
Institute for Pharmacology and Toxicology, Goethe University, Frankfurt am Main, Germany.

Sylvia Hartmann (S)

Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany.

Lionel Huber (L)

Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.

Eva Kärgel (E)

Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

Simone Lusatis (S)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.
Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.
Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany.

Daniel Noerenberg (D)

Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.

Nadine Obier (N)

Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

Ulrich Pannicke (U)

Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.

Anja Fischer (A)

Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany.

Anja Reisser (A)

Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany.

Andreas Rosenwald (A)

Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany.

Klaus Schwarz (K)

Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg-Hessen, Ulm, Germany.

Srinivasan Sundararaj (S)

Research School of Biology, The Australian National University, Canberra, ACT, Australia.

Andre Weilemann (A)

Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.

Wiebke Winkler (W)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.
Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.
Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany.

Wendan Xu (W)

Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.

Georg Lenz (G)

Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.

Klaus Rajewsky (K)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Immune Regulation and Cancer, 13125, Berlin, Germany.

Wyeth W Wasserman (WW)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada.

Peter N Cockerill (PN)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

Claus Scheidereit (C)

Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

Reiner Siebert (R)

Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany.
Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany.

Ralf Küppers (R)

German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany.

Rudolf Grosschedl (R)

Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.

Martin Janz (M)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.
Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.
Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany.

Constanze Bonifer (C)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

Stephan Mathas (S)

Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany. stephan.mathas@charite.de.
Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany. stephan.mathas@charite.de.
Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany. stephan.mathas@charite.de.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. stephan.mathas@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH